{"id":59803,"date":"2024-02-28T06:16:55","date_gmt":"2024-02-28T06:16:55","guid":{"rendered":"https:\/\/medsname.com\/olanzap\/"},"modified":"2026-04-30T10:23:54","modified_gmt":"2026-04-30T10:23:54","slug":"olanzap","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/olanzap\/","title":{"rendered":"Olanzap"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 R\u0103spuns rapid<\/h3>\n

Olanzap (Olanzapine 2.5 \/ 5 \/ 7.5 \/ 10 \/ 15 \/ 20 mg) is an atypical antipsychotic for schizophrenia, bipolar mania and maintenance, treatment-resistant depression (with fluoxetine), and acute agitation. The most robust antipsychotic effect of the atypicals \u2014 but the heaviest metabolic burden.<\/p>\n<\/div>\n

\nCe beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate ale clien\u021bilor<\/a>\n<\/div>\n

\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n

De ce s\u0103 comanzi de la MedsBase<\/h3>\n

Olanzap at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a> \u2014 perioad\u0103 de livrare de 20 de zile lucr\u0103toare sau retrimitem f\u0103r\u0103 costuri suplimentare \u2014 \u0219i se calific\u0103 pentru programul nostru de loialitate pentru clien\u021bi<\/a>. Livr\u0103rile sunt disponibile \u00een majoritatea destina\u021biilor la nivel mondial.<\/p>\n

What Olanzap is and how it works<\/h2>\n

Olanzap is an olanzapine tablet supplied by Sun Pharma. Available strengths: 2.5 \/ 5 \/ 7.5 \/ 10 \/ 15 \/ 20 mg<\/strong>. Olanzapine is a thienobenzodiazepine atypical antipsychotic with strong D2 antagonism, strong 5-HT2A antagonism, and substantial H1 (sedation, weight gain), M1 (anticholinergic), and \u03b11 (orthostasis) blockade. The H1+M1 receptor profile is responsible both for its calming\/sedative effect (useful in acute agitation) and for its metabolic burden.<\/p>\n

Indica\u021bii \u0219i dozaj<\/h2>\n\n\n\n\n\n\n\n\n\n\n
Indica\u021bie<\/th>\nDoza ini\u021bial\u0103<\/th>\n\u021aint\u0103<\/th>\nMaxim<\/th>\n<\/tr>\n<\/thead>\n
Schizofrenie (adul\u021bi)<\/td>\n5\u201310 mg OD<\/td>\n10\u201320 mg o dat\u0103 pe zi<\/td>\n20 mg<\/td>\n<\/tr>\n
Schizofrenie (adolescent \u2265 13 ani)<\/td>\n2.5\u20135 mg OD<\/td>\n10 mg OD<\/td>\n20 mg<\/td>\n<\/tr>\n
Manie bipolar\u0103 (adult)<\/td>\n10\u201315 mg pe zi<\/td>\n10\u201320 mg o dat\u0103 pe zi<\/td>\n20 mg<\/td>\n<\/tr>\n
Acute agitation (IM)<\/td>\n10 mg IM<\/td>\n\u2014<\/td>\n3 doze\/24h<\/td>\n<\/tr>\n
Treatment-resistant depression (with fluoxetine)<\/td>\n5 mg + 20 mg fluoxetine<\/td>\n5\u201318 mg<\/td>\n18 mg<\/td>\n<\/tr>\n
Pacien\u021bi v\u00e2rstnici<\/td>\n2.5\u20135 mg OD<\/td>\n5\u201310 mg OD<\/td>\n\u00een func\u021bie de tolerabilitate<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Considera\u021bii importante de siguran\u021b\u0103<\/h2>\n
\nFDA black-box \u2014 psihoz\u0103 asociat\u0103 demen\u021bei<\/strong><\/p>\n

Toate antipsihoticele atipice poart\u0103 un avertisment FDA black-box pentru mortalitate crescut\u0103 (\u00een principal cardiovascular\u0103 \u0219i infec\u021bioas\u0103) atunci c\u00e2nd sunt utilizate pentru tratarea tulbur\u0103rilor de comportament la adul\u021bii \u00een v\u00e2rst\u0103 cu demen\u021b\u0103. Antipsihoticele atipice nu sunt aprobate pentru psihoza sau agita\u021bia asociat\u0103 demen\u021bei<\/strong>. Utilizarea \u00een aceast\u0103 popula\u021bie este off-label, de ultim\u0103 instan\u021b\u0103, limitat\u0103 \u00een timp \u0219i necesit\u0103 o discu\u021bie explicit\u0103 despre raportul risc-beneficiu.<\/p>\n<\/div>\n

\nHeaviest metabolic burden of the atypicals<\/strong><\/p>\n

Olanzapine produces the most weight gain (typically 4\u201310 kg in the first 6 months, sometimes far more), the most insulin resistance, and the most lipid disturbance of any commonly-used antipsychotic. Patients can develop type 2 diabetes within months of initiation. Mandatory monitoring: weight at every visit; fasting glucose \/ HbA1c and fasting lipids at baseline, 12 weeks, then 6-monthly.<\/strong> Counsel about diet and exercise from initiation.<\/p>\n<\/div>\n

\nSedation and anticholinergic burden<\/strong><\/p>\n

Strong sedation in the first 1\u20132 weeks. Anticholinergic effects (dry mouth, constipation, urinary hesitancy) are universal. Both lessen but do not disappear.<\/p>\n<\/div>\n

\nOlanzapine + benzodiazepine IM \u2014 caution<\/strong><\/p>\n

Combining IM olanzapine with parenteral benzodiazepines has produced cases of severe hypotension, respiratory depression, and death. If both are clinically necessary in acute agitation, separate by \u2265 1 hour and monitor closely.<\/p>\n<\/div>\n

Efecte secundare frecvente<\/h2>\n